New York—June 13, 2011
The Hospital, internationally recognized for its leadership in the fields of orthopedics and rheumatology, will bring together a multidisciplinary group of thought leaders from the United States, Canada, Europe and Australia. Renowned physicians, scientists and industry leaders will describe current research, the most promising avenues for future investigation, the latest diagnostic tools and treatments, public health strategies and the most recent information on preventing OA.
“Public health data indicate that the prevalence, impact and economic consequences of osteoarthritis are expected to rise dramatically within the next several decades. Clearly, understanding and preventing this disease is an urgent research challenge,” said Steven Goldring, M.D., chief scientific officer at Hospital for Special Surgery and co-director of the conference.
“By bringing together a group of leading international experts, we will develop a consensus document on future directions for OA research, prevention and treatment,” said Timothy Wright, Ph,D., Kirby chair of orthopedic biomechanics at HSS and co-director of the event.
Orthopedic surgeons, heumatologists, scientists and biomechanical engineers— experts in the major research and clinical aspects of the disease—as well as leaders from the pharmaceutical, device and insurance industries will be among 35 speakers discussing a wide range of topics. The two-day-long event will take place at the Richard Menschel Conference Center at HSS on Friday, June 17, starting at 9 a.m., and on Saturday, June 18, starting at 8 a.m.
Among the subjects to be explored:
The conference will feature distinguished speakers from the National Institutes of Health, the Arthritis Foundation, Hospital for Special Surgery, Rush Medical Center, Brigham and Women’s Hospital, Tufts, Wake Forest, Duke University, McGill University in Canada, the University of Sydney, Genzyme Biosurgery, Pfizer, Inc., Zimmer, Inc., and Aetna.
“We believe the Osteoarthritis Summit will provide vital information about the research, care and innovation necessary to improve the lives of millions of people suffering from OA,” Dr. Goldring said. “Hospital for Special Surgery is proud to be a leader in raising awareness of osteoarthritis and promoting critical research and best practices in patient care.”
For a complete list of topics and speakers, go tohttp://www.hss.edu/files/OASummitAgenda2011.pdf
Osteoarthritis (OA), the most common form of arthritis, is a serious and painful joint disease that limits mobility and impairs quality of life. Most often affecting the hip and knee, half of all adults will develop symptomatic OA of the knee at some point in their lives.
The socioeconomic burden of the disease is staggering. The economic impact is $128 billion: $81 billion for direct health care expenditures and $47 billion in indirect costs related to lost earnings. OA results in 992,000 hospitalizations and 44 million outpatient visits annually. More than 770,000 hip and knee replacements are performed each year in the United States.
About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 2 in rheumatology by U.S. News & World Report (2016-2017), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at www.hss.edu.